Press Releases

Share

Aa-+
  • National Institutes of Health (NIH) helps fund Colcorona COVID-19 clinical study

    May 5, 2020

    Study examines if colchicine, a common gout medication, can reduce complications associated with COVID-19, slow disease progression, and save patient lives

    Read more

  • Sophie Desmarais raises $1,942,000 for research at the Montreal Heart Institute

    April 22, 2020

    The Montreal Heart Institute Foundation is proud to announce that in addition to a generous $1 million contribution officialized on April 3rd, philanthropist Sophie Desmarais has raised even more funds to support the Montreal Heart Institute’s Research Centre and its Colcorona clinical study. Ms. Desmarais recently invited donors to contribute to this major project. And the community responded by donating $471,000, which was then matched by Ms. Desmarais, bringing the total amount to $1,942,000.

    Read more

  • Sophie Desmarais donates $1 million for research at the Montreal Heart Institute

    April 3, 2020

    The Montreal Heart Institute Foundation is proud to announce today that philanthropist Sophie Desmarais will be supporting the Montreal Heart Institute’s research projects thanks to a $1 million donation that will be used by the Research Centre for their ColCorona study. On March 23, the Institute’s Research Centre launched this ground-breaking clinical study in order to help patients infected with COVID-19.

    Read more

  • New clinical study: Potential treatment for coronavirus will be tested in Canada as of today Share

    March 23, 2020

    The Montreal Heart Institute announces that its Research Center is launching today a COVID-19 clinical study in Canada to determine whether short-term treatment would reduce the risk of pulmonary complications and related deaths. 

    The clinical study, named COLCORONA, coordinated by the Montreal Health Innovations Coordinating Center (MHICC) is funded by the Government of Quebec and supported by Pharmascience and CGI. 

    Read more

  • New clinical study: Potential treatment for coronavirus will be tested in Canada as of today

    March 23, 2020

    The Montreal Heart Institute announces that its Research Center is launching today a COVID-19 clinical study in Canada to determine whether short-term treatment would reduce the risk of pulmonary complications and related deaths. 

    The clinical study, named COLCORONA, coordinated by the Montreal Health Innovations Coordinating Center (MHICC) is funded by the Government of Quebec and supported by Pharmascience and CGI. 

    Read more

  • COVID-19 - IMPORTANT INFORMATION

    March 18, 2020

    In order to lower the epidemic curve and to protect its staff and customers, the ICM is implementing exceptional and temporary measures.

    Visitors: On March 14, 2020, in order to protect the most vulnerable, the Government of Quebec announced the suspension of visits to all hospital centers.

    EPIC Center: The EPIC Center suspends its sports activities and its secondary prevention and diabetes clinics from March 13, 2020.

    Read more

  • A world-class discovery in Montreal

    November 16, 2019

    The COLCOT clinical trial demonstrates that it is possible to reduce the risk of cardiovascular events with a low-cost drug already available.

    Read more

  • The Montreal Heart Institute stands out for its excellence in research and receives a 15.4M$ grant from the Government of Quebec for two major projects in precision medicine

    June 4, 2019

    Pierre Fitzgibbon, Québec Minister of Economy and Innovation, announced today at the BIO International Convention held in Philadelphia (PA, USA), that Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute (MHI), received two grants from the Government of Quebec’s Fonds d’accélération des collaborations en santé (FACS). Totalling $15.4 million, these grants will be used to lead two major projects worth more than $36.6 million to fight cardiovascular diseases, the number one cause of death worldwide.

    Read more

  • Discovery Explaining the Potential Cardiovascular Benefits of a Precision Therapy Based on the Genetic Profile

    April 27, 2018

    Researchers at the Montreal Heart Institute announced today that they have discovered the mechanism for the protective effects of reduced activity of the ADCY9 gene in atherosclerosis resulting from accumulation of fat in the artery walls. Indeed, a reduction of 65% of atherosclerosis occurs when the ADCY9 gene is not functional in mice, but only when another gene (CETP) is also absent. This benefit is explained by a marked reduction of inflammation in the arteries. These results have been published in the prestigious American scientific journal Circulation.

    Read more

  • Ceapro Inc. Announces Important Collaboration with Prestigious Montreal Heart Institute

    April 19, 2018

    Ceapro Inc. (TSX-V: CZO), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has established a long-term formal collaboration with the prestigious Montreal Heart Institute (MHI).

    Read more

Pages